Bortezomib (Velcade) for relapsed and refractory multiple myeloma - horizon scanning review
NHSC
Record ID 32004000892
English
Authors' objectives:
This study aims to summarise the currently available evidence on bortezomib (Velcade) for relapsed and refractory multiple myeloma.
Authors' recommendations:
Bortezomib is the first of a new class of antineoplastic agents called proteasome inhibitors. It is administered intravenously at a dose of 1.3 mg/m2 twice weekly for 2 weeks followed by a 10 day rest period (one cycle). The number of cycles will be limited to 8.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Multiple Myeloma
- Bortezomib
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.